drugset
drugset / Trial / NCT04313166

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

NCT04313166 ↗

Phase 2 Completed 55 enrolled Collaborative Medicinal Development Pty Limited
NaSingle-groupOpen-labelTreatment

Summary

Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001

Timeline

Start
2020-03-19
Primary completion
2021-11-18
Completion
2022-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ATSM COPPER (II) Small molecule — —

Indications

amyotrophic lateral sclerosis